Bristol-Myers Squibb (BMY -0.08%) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With a large repertoire of medicines on the market, and a constant stream of programs approaching maturity and a shot at getting approved for sale, there's no question that the business will continue to create drugs that are in demand around the world.But solid companies don't always make for the perfect investments, especially when investors have outsized expectat ...

The sell-offs of these stocks were driven by issues that were never going to last.Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold forever is a different story. For your truly long-term holdings, you'll want companies that are not only leading names with staying power, but that also operate in resilient markets -- a rarer set of criteria.Of course, if such a stock is on sale at the time you're ready to take the plunge, so much the ...

POLAND - 2024/11/22: In this photo illustration, the Bristol-Myers Squibb company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forward expected earnings (2025), versus 14.7x for JNJ. However, ...

When I last wrote about the pharmaceuticals company Bristol-Myers Squibb Company (NYSE: BMY ) in August, I had given it a Sell rating for the short term. This was based on the likelihood of a price drop on the releaseManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Gia ...

Generating thousands of dollars of recurring income can be a great way to make you less reliant on employment income or retirement benefits. If you have savings that you can afford to invest in stocks, there are multiple high-yielding dividend investments to consider right now. While many investors have been focusing on growth stocks and hype surrounding artificial intelligence, dividend stocks have been on the back burner of late, which could make now an advantageous time to invest in them.Three dividend s ...

Summary of Bristol-Myers Squibb Company Conference Call Company Overview - **Company**: Bristol-Myers Squibb Company (NYSE: BMY) - **Event**: Jefferies London Healthcare Conference - **Date**: November 19, 2024 - **Participants**: David Elkins (CFO), Unidentified Company Representative Key Points Industry and Company Performance - The focus for the year is on execution, with two strong quarters indicating a transformation within the company [2][11] - The growth portfolio has seen a **20% increase** in constant currency, now representing nearly **50%** of the company's revenue [3][12] - Legacy portfolio remains a significant cash generator for the business [2] Product Pipeline and Upcoming Approvals - **Cobenfy**: Recently acquired product with promising feedback from physicians; expected to be a multibillion-dollar product with multiple indications [3][6] - Upcoming **PDUFA date** for subcutaneous Opdivo in December, aimed at improving patient experience and reducing healthcare costs [4][29] - Strong growth in key products: - **Camzyos**: Cardiovascular drug for obstructive HCM, doubled sales compared to last year [5] - **Breyanzi**: Cell therapy for large B-cell lymphoma, also doubled sales [5] - **Reblozyl**: First-line MDS treatment, doubled sales [5] Future Growth and Clinical Trials - Multiple Phase III data readouts expected between now and 2026, including indications for schizophrenia and Alzheimer's disease [6][12] - **Milvexian**: Expansion of patient population with important Phase III studies planned for ACS and secondary stroke prevention [7][12] - Focus on driving efficiencies with a **$1.5 billion savings initiative** aimed at improving ROI and growth profile [9] Business Development Strategy - Significant business development activity with nearly **$30 billion** in acquisitions over recent years [14] - Current focus on integrating recent acquisitions and paying down **$10 billion** in debt by 2026 [15][14] - Future strategy includes smaller bolt-on acquisitions and collaborations once integration is complete [15] Market Position and Competitive Landscape - The company is well-positioned in therapeutic areas with high unmet medical needs, particularly in solid tumor oncology and neuro products [17][18] - Cobenfy is expected to address significant unmet needs in Alzheimer's disease and other indications, with potential for multibillion-dollar revenue [18][19] Regulatory Environment and Industry Resilience - The company remains confident in navigating regulatory changes and emphasizes the resilience of the healthcare industry [33] - Focus on delivering innovative medicines that address serious unmet medical needs while managing costs [33] Conclusion - Bristol-Myers Squibb is poised for growth with a strong pipeline, strategic focus on execution, and a commitment to addressing unmet medical needs in various therapeutic areas. The company is actively managing its business development strategy while preparing for significant product launches and clinical trial outcomes in the coming years [2][12][15].

On October 31, Bristol-Myers Squibb (NYSE: BMY ) released financial results for the third quarter of 2024 , which not only beat Wall Street analysts' expectations by a wide margin but also pleasantly surprised me.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceu ...

Core Insights - Bristol Myers Squibb (BMY) stock rose 10% following AbbVie's failure in mid-stage clinical trials for its schizophrenia drug Emraclidine, which enhances BMY's position after receiving FDA approval for its own schizophrenia drug, Cobenfy, expected to bring a 20% upside to BMY stock [1][6] Financial Performance - BMY stock has declined 11% since January 2023, from $67 to around $60, while the S&P 500 increased by 57% during the same period [2] - The company's price-to-sales (P/S) ratio fell by 15% to 2.6x, while revenue increased by 1% from $46 billion to $47 billion, and share count reduced by 4.1% due to $13 billion in share repurchases [2] Sales Growth Drivers - BMY's revenue growth has been limited to 1% since 2022, primarily due to declining sales of legacy drugs like Revlimid, while Eliquis generated over $12 billion in sales last year and is expected to continue growing [4][5] - New drugs such as Camzyos, Sotyktu, and Opdualag are projected to exceed $1 billion in sales each by 2026, and BMY has made three acquisitions to enhance its pipeline, now with over 50 compounds in development [5] Profit Margins - BMY's operating margin has contracted from 19.7% in 2022 to 15.3% currently, influenced by increased expenses related to research and development and acquisitions [7] - The company anticipates adjusted earnings per share for 2024 to be between $0.75 and $0.95, significantly lower than the $7.51 reported in 2023 due to a one-time charge of $12.1 billion for the acquisition of Karuna [7] Financial Risk Assessment - BMY's cash reserves decreased from $9.3 billion in 2022 to $8.1 billion, while total debt rose from $40.7 billion to $51.4 billion, indicating a high debt level but a reasonable financial risk profile [8] Stock Growth Potential - BMY stock has increased by 21% this year, underperforming the S&P 500's 26% rise, with historical volatility reflected in returns of 3% in 2021, 19% in 2022, and -26% in 2023 [9][10] - The current valuation of BMY stock at around $60, trading at 2.5x revenues, aligns with its average P/S ratio over the past three years, suggesting that the stock is appropriately priced given the mix of new drug opportunities and challenges from legacy drugs [10]

Key Points **Industry/Company Involved**: - Bristol-Myers Squibb Company (NYSE:BMY) **Core Points and Arguments**: - **Pipeline Strength and Portfolio Changes**: Bristol Myers Squibb has strengthened its pipeline with the addition of companies like Mirati, Karuna, and RayzeBio, expanding beyond immune-oncology. The company has also prioritized certain programs and removed others that were not meeting expectations. - **Research and Development (R&D) Productivity**: The company aims to increase the number of Investigational New Drug (IND) applications, reduce the time from IND approval to first indication approval, and increase the positive outcomes from INDs. - **COBENFY**: COBENFY, a treatment for schizophrenia, has shown promising results and is expected to have multiple indications over the next decade. The company is also exploring its potential in bipolar mania, Alzheimer's disease agitation, and other conditions. - **Milvexian**: Milvexian, a Factor 11 inhibitor, is in Phase III clinical trials for atrial fibrillation, acute coronary syndrome, and stroke prevention. The company remains confident in the drug's potential despite recent competitive challenges. - **CAR-T Therapy**: Bristol Myers Squibb is exploring the potential of CAR-T therapy in autoimmune diseases, including lupus and multiple sclerosis. The company has seen promising results in early trials and is actively researching other mechanisms for resetting immune memory. - **Immunology**: The company is developing a range of immunology assets, including Sotyktu, nivolumab, and relatlimab. The company is also exploring combinations of these drugs to improve outcomes for patients with various conditions. - **Multiple Myeloma**: Bristol Myers Squibb is taking a multi-modality approach to multiple myeloma, including small molecules, cell therapies, and combinations of these therapies. - **Hematology**: The company has a robust pipeline in hematology, including Golcadomide, mezigdomide, and BCL6 LDD. - **Cardiovascular Disease**: The company is developing MYK-224, a second cardiac myosin inhibitor, for the treatment of heart failure with preserved ejection fraction (HFpEF). - **Respiratory Diseases**: The company is developing LPA1, a treatment for idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PPF). **Other Important Points**: - **IRA Legislation**: The company expressed concerns about the potential impact of the IRA legislation on small molecule drugs and the potential for changes to the nine-year versus 13-year discussion. - **ASH Meeting**: The company is expected to present data on various assets at the upcoming ASH meeting, including Golcadomide, mezigdomide, GPRC5D, and BCL6 LDD. - **Future Data**: The company highlighted several data sets that it is excited about in the next 12 to 18 months, including milvexian, GPRC5D, COBENFY, SLE for Sjogren's, anti-TAL, FAAH and MAGLipase inhibitor, radioligand therapy in breast cancer and small cell lung cancer, GPC3 for radioligand therapy, and CCR8 in oncology.

Core Viewpoint - Bristol Myers Squibb (BMY) has shown strong performance in the biotech sector, with a notable increase in stock price and positive quarterly results driven by newer drugs and strategic acquisitions [1][2][3]. Financial Performance - BMY's stock has risen 20.1% over the past six months, significantly outperforming the industry growth of 5.3% [1]. - The company reported better-than-expected third-quarter results, leading to an increase in annual earnings guidance [2]. - The Zacks Consensus Estimate for 2024 earnings per share (EPS) has increased from $0.76 to $0.88 over the past 30 days [13]. Drug Portfolio and Growth Drivers - New drugs such as Reblozyl, Breyanzi, Camzyos, and Opdualag are crucial for stabilizing revenue as legacy drugs face generic competition [3][4]. - Opdualag has achieved a 30% market share in the first-line melanoma setting in the U.S., contributing significantly to revenue [4]. - The recent FDA approval of Cobenfy for schizophrenia expands BMY's portfolio and validates its acquisition strategy [6]. Strategic Acquisitions - BMY has made significant acquisitions, including Mirati Therapeutics for $4.8 billion, enhancing its oncology portfolio with Krazati [7]. - The acquisition of RayzeBio added a proprietary radiopharmaceutical platform to BMY's offerings [7]. Challenges and Competition - BMY's legacy drug Revlimid faces generic competition, impacting its sales despite a positive earnings report [8]. - Eliquis, a major revenue contributor, is expected to face generic competition later in the decade [9]. - Other drugs like Sprycel and Pomalyst are also encountering challenges due to generics [10]. Cost Management and Debt - A strategic cost-reduction plan aims to save approximately $1.5 billion by the end of 2025, focusing on long-term returns and operational optimization [11]. - As of September 30, 2024, BMY's total debt-to-total capital ratio was 74.3%, raising concerns about its financial leverage [12]. Valuation Metrics - BMY's shares currently trade at a price/earnings ratio of 8.63x forward earnings, lower than the large-cap pharma industry average of 17.57x [13]. Conclusion - The recent stock rally indicates potential for a turnaround for BMY, with newer drugs expected to drive future growth despite the challenges posed by generic competition [16].